FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990991119> ?p ?o ?g. }

• W2990991119 abstract "Abstract Backgrounds The aberrant activation of complement system is critically involved in lupus nephropathy. Recent study showed complement C3 inhibitor was effective in the treatment of lupus nephropathy. In this study, we investigate the effect of a novel complement C3 inhibitor, CRIg/FH, in the treatment of lupus nephropathy in MRL/lpr lupus mice. Methods We treated MRL/lpr female mice with a dose escalation of CRIg/FH (10, 5 and 2 mg/kg) by intraperitoneal injection twice weekly since 12 weeks age. In addition, MRL/lpr mice treated with intraperitoneal injection of normal saline or oral prednisone, along with C57BL/6 J healthy mice were maintained to serve as controls. We started 8-h urine collection weekly to screen proteinuria by measuring the levels of urine urea/creatinine. Serum samples was collected at week 16 and 20 to measure levels of urea nitrogen, creatinine, and immunological markers (C3, C4, A-ds-DNA) before the mice were sacrificed at 20 weeks age to collect kidneys for histopathological examinations. Results Overt skin lesions were observed in MRL/lpr mice treated with normal saline, while skin lesion was not observed in CRIg/FH treated MRL/lpr mice. There was no overt proteinuria observed in MRL/lpr mice treated with CRIg/FH. Serum creatinine and BUN levels in MRL/lpr mice was maintained in highest CRIg/FH dose (10 mg/kg twice a week) to be significantly lower than that in prednisone treated MRL/lpr mice at 20 weeks age. In addition, CRIg/FH treatment in MRL/lpr mice results in a significantly elevated serum C3 and C4 levels when compared to prednisone treatment at both 16 and 20 weeks. Furthermore, our study identified that serum level of A-ds-DNA was also significantly lower in CRIg/FH treatment than that in predisone treated MRL/lpr mice. Renal pathology confirmed that kidneys from CRIg/FH treated MRL/lpr mice suffered less from nephritis and complement disposition. Conclusion Our results showed that the complement inhibitor CRIg/FH can protect MRL/lpr mice from lupus nephropathy by preserving renal function and glomerulus complement activation. Our findings support the positive effect of complement inhibitors in the treatment of lupus nephropathy." @default.
• W2990991119 created "2019-12-05" @default.
• W2990991119 creator A5001047616 @default.
• W2990991119 creator A5032519062 @default.
• W2990991119 creator A5034042779 @default.
• W2990991119 creator A5044812188 @default.
• W2990991119 creator A5055644158 @default.
• W2990991119 creator A5063470398 @default.
• W2990991119 creator A5082227068 @default.
• W2990991119 creator A5090050137 @default.
• W2990991119 date "2019-11-21" @default.
• W2990991119 modified "2023-10-18" @default.
• W2990991119 title "The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice" @default.
• W2990991119 cites W1515279716 @default.
• W2990991119 cites W1967076712 @default.
• W2990991119 cites W1974553402 @default.
• W2990991119 cites W1974767230 @default.
• W2990991119 cites W1989717223 @default.
• W2990991119 cites W2008168218 @default.
• W2990991119 cites W2010241440 @default.
• W2990991119 cites W2016318369 @default.
• W2990991119 cites W2023138787 @default.
• W2990991119 cites W2034813612 @default.
• W2990991119 cites W2060179486 @default.
• W2990991119 cites W2083761482 @default.
• W2990991119 cites W2092715423 @default.
• W2990991119 cites W2095409772 @default.
• W2990991119 cites W2095473607 @default.
• W2990991119 cites W2143601906 @default.
• W2990991119 cites W2167174647 @default.
• W2990991119 cites W2417465198 @default.
• W2990991119 cites W2462648395 @default.
• W2990991119 cites W2465861967 @default.
• W2990991119 cites W2593014595 @default.
• W2990991119 cites W2742950097 @default.
• W2990991119 cites W2772102828 @default.
• W2990991119 cites W2789927285 @default.
• W2990991119 cites W2827929011 @default.
• W2990991119 cites W2883447784 @default.
• W2990991119 cites W2980547919 @default.
• W2990991119 cites W319718096 @default.
• W2990991119 doi "https://doi.org/10.1186/s12882-019-1599-0" @default.
• W2990991119 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6873683" @default.
• W2990991119 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31752725" @default.
• W2990991119 hasPublicationYear "2019" @default.
• W2990991119 type Work @default.
• W2990991119 sameAs 2990991119 @default.
• W2990991119 citedByCount "13" @default.
• W2990991119 countsByYear W29909911192020 @default.
• W2990991119 countsByYear W29909911192021 @default.
• W2990991119 countsByYear W29909911192022 @default.
• W2990991119 countsByYear W29909911192023 @default.
• W2990991119 crossrefType "journal-article" @default.
• W2990991119 hasAuthorship W2990991119A5001047616 @default.
• W2990991119 hasAuthorship W2990991119A5032519062 @default.
• W2990991119 hasAuthorship W2990991119A5034042779 @default.
• W2990991119 hasAuthorship W2990991119A5044812188 @default.
• W2990991119 hasAuthorship W2990991119A5055644158 @default.
• W2990991119 hasAuthorship W2990991119A5063470398 @default.
• W2990991119 hasAuthorship W2990991119A5082227068 @default.
• W2990991119 hasAuthorship W2990991119A5090050137 @default.
• W2990991119 hasBestOaLocation W29909911191 @default.
• W2990991119 hasConcept C111684460 @default.
• W2990991119 hasConcept C126322002 @default.
• W2990991119 hasConcept C134018914 @default.
• W2990991119 hasConcept C159654299 @default.
• W2990991119 hasConcept C189446657 @default.
• W2990991119 hasConcept C203014093 @default.
• W2990991119 hasConcept C2776912625 @default.
• W2990991119 hasConcept C2778720950 @default.
• W2990991119 hasConcept C2779134260 @default.
• W2990991119 hasConcept C2779561371 @default.
• W2990991119 hasConcept C2779912601 @default.
• W2990991119 hasConcept C2780091579 @default.
• W2990991119 hasConcept C2780306776 @default.
• W2990991119 hasConcept C2781184683 @default.
• W2990991119 hasConcept C555293320 @default.
• W2990991119 hasConcept C71924100 @default.
• W2990991119 hasConceptScore W2990991119C111684460 @default.
• W2990991119 hasConceptScore W2990991119C126322002 @default.
• W2990991119 hasConceptScore W2990991119C134018914 @default.
• W2990991119 hasConceptScore W2990991119C159654299 @default.
• W2990991119 hasConceptScore W2990991119C189446657 @default.
• W2990991119 hasConceptScore W2990991119C203014093 @default.
• W2990991119 hasConceptScore W2990991119C2776912625 @default.
• W2990991119 hasConceptScore W2990991119C2778720950 @default.
• W2990991119 hasConceptScore W2990991119C2779134260 @default.
• W2990991119 hasConceptScore W2990991119C2779561371 @default.
• W2990991119 hasConceptScore W2990991119C2779912601 @default.
• W2990991119 hasConceptScore W2990991119C2780091579 @default.
• W2990991119 hasConceptScore W2990991119C2780306776 @default.
• W2990991119 hasConceptScore W2990991119C2781184683 @default.
• W2990991119 hasConceptScore W2990991119C555293320 @default.
• W2990991119 hasConceptScore W2990991119C71924100 @default.
• W2990991119 hasIssue "1" @default.
• W2990991119 hasLocation W29909911191 @default.
• W2990991119 hasLocation W29909911192 @default.
• W2990991119 hasLocation W29909911193 @default.
• W2990991119 hasLocation W29909911194 @default.
• W2990991119 hasLocation W29909911195 @default.

• next